Core of the investment with a total volume of about 3 million € is the construction of a new production line beginning with a two-stage evaporation system and resulting in a modern pharmaceutical final products plant in supplementation to the GMP-certified plant concept.

"After the completed management buy-out and enthused by the successful GMP-certification for an API manufacturer under the German Drug Act, AMINO has decided to invest in the expansion and upgrading of its plants," says Dr. Lutz Thomas, the managing director of AMINO GmbH. “At the same time, these measures will create new jobs and sustain the profile of the AMINO GmbH regionally and in the international pharmaceutical industry”.

The strengthening of the business development team and the scheduled commissioning of the new facilities will enable AMINO to offer a large number of new amino acids and related substances in the short- and medium-term.

AMINO GmbH, headquartered in Frellstedt, Germany, is a fully integrated producer of specialty amino acids with natural biological origins. The company is dedicated to producing pharmaceutical-grade and infusion-grade amino acids under strict cGMP standards using the best extraction and purification technology (concentrating on vegetable raw materials) or state-of-the-art biotechnology/fermentation as appropriate.